CD22 and lymphoma: An earlier version of an anti-CD22 x anti-CD20 bsHexAb, 22-(20)-(20), which has four Fabs of veltuzumab fused to the Fc of epratuzumab, demonstrated potent killing of lymphoma cell lines in vitro[49].